IMMUNE-COMPLEX-MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS

Clinical trials for IMMUNE-COMPLEX-MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS explained in plain language.

Never miss a new study

Get alerted when new IMMUNE-COMPLEX-MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS trials appear

Sign up with your email to follow new studies for IMMUNE-COMPLEX-MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug offers hope for Long-Term control of devastating kidney diseases

Disease control Recruiting now

This study is for people who have already been in a related trial for the drug iptacopan. It aims to see how safe and effective the drug is over many years for two rare and serious kidney diseases, C3G and IC-MPGN. The goal is to control the disease, protect kidney function, and …

Matched conditions: IMMUNE-COMPLEX-MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS

Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Mar 30, 2026 14:35 UTC

IMMUNE-COMPLEX-MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS

Get alerted when new IMMUNE-COMPLEX-MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS trials appear

New drug offers hope for Long-Term control of devastating kidney diseases